Taipei Exchange Launches Dedicated Sustainable Bond Segment to Further Issuing Momentum
The Taipei Exchange, TPEx, launched a dedicated segment for sustainable bonds, celebrating on May 18 with the debut of three social bond listings. The segment marks a milestone for Taiwan’s socially responsible investment and is in accordance with a plan announced by the Taiwanese government’s Financial Supervisory Commission (FSC). The commission’s plan, named the Green Finance Action Plan 2.0, was announced in August 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005043/en/
Taipei Exchange launches dedicated sustainable bond segment to further issuing momentum. (Graphic: Business Wire)
TPEx Chairman Philip Chen said in a statement announcing the new segment, “After accomplishing the mechanism regarding social bonds, the last piece of the puzzle, TPEx has integrated the regulations of Green Bonds, Sustainability Bonds, and Social Bonds and launched this segment exclusively for ESG concept bonds.” Chen went on to highlight TPEx’s market acclaim for launching Green Bond and Sustainability Bond operational directions in 2017 and 2020 respectively, which were in line with the ICMA’s GBP and SBG. The total outstanding amount of listed sustainable bonds has steadily grown, exceeding NT$207bn (US$7bn), according to Chen.
The first batch of three social bonds listed on TPEx is primarily funding socioeconomic advancement projects related to the global COVID-19 pandemic, projects such as increasing access to loans, providing job opportunities and raising the availability of affordable housing.
FSC Chairman Dr. Tien-Mu Huang said, “FSC fully supports financial innovation and product diversity. The Sustainable Bond Segment at TPEx provides the market with a clearer, more complete and consistent regulatory mechanism, facilitating easier compliance for issuers. This subsequently serves to direct funds to eco-friendly and socially beneficial projects, helping achieve the goals of Green Finance Action Plan 2.0 tremendously.” Mrs. Tania Berchem from the Luxemburg Trade and Investment Office in Taipei, Mr. Nicholas Pfaff from ICMA, and Mr. Sean Kidney from CBI all sent their congratulatory messages to TPEx for the dedicated segment.
Meanwhile, TPEx has modernized its sustainable bonds website (https://www.tpex.org.tw/web/bond/sustainability/index.php?l=en-us), improving all relevant information for clarity and accessibility. The updated website is bilingual, and key features have been added which include issuance status and bond framework information, assessment opinions from external reviewers, market reports, and access to current sustainability studies and research reports. Speaking of the new website, Chen added, “In facilitating responsible investing, we hope to offer a full array of information to enhance transparency while simultaneously raising investors’ social awareness.”
About the Taipei Exchange
Established in 1994, the Taipei Exchange is a member of the World Federation of Exchanges. The exchange has grown with a vision of sustainability to meet the diverse needs of issuers and investors, and has long been dedicated to fostering emerging, high-tech and creative industries by providing a viable channel for raising capital. The exchange has also established a fast-growing bond market. For more information, visit: https://www.tpex.org.tw/web/index.php?l=en-us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005043/en/
Contact information
Tinna Chen: tinnachen@tpex.org.tw
Iris Yang: irisyang@tpex.org.tw
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom